Syngene International Extends Long-term Research Collaboration with Bristol Myers Squibb until 2035
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced the extension of its strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle, including discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services. This collaboration marks the next phase of growth for Syngene, reinforcing its position as a strategic partner delivering integrated, end-to-end scientific and manufacturing solutions. The collaboration began in 1998 and has evolved into a major strategic R&D site for Bristol Myers Squibb, contributing to discovery, preclinical development, and patent filings across therapeutic areas.
Key Highlights
- Syngene International extends its long-term research collaboration with Bristol Myers Squibb until 2035
- The expanded agreement broadens the scope of integrated services across the drug development lifecycle
- The collaboration began in 1998 and has evolved into a major strategic R&D site for Bristol Myers Squibb
- The Biocon Bristol Myers Squibb Research and Development Center (BBRC) contributes to discovery, preclinical development, and patent filings across therapeutic areas
- The BBRC houses around 700 Syngene scientists working as an extension of Bristol Myers Squibb’s global research organization